Craig Hallum reaffirmed their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a report published on Thursday morning, The Fly reports. Craig Hallum currently has a $68.00 price target on the health services provider’s stock, up from their prior price target of $55.00.
Other equities analysts have also recently issued reports about the stock. Oppenheimer Holdings, Inc. reissued a buy rating and set a $60.00 price target on shares of Amedisys in a research report on Friday, September 15th. Jefferies Group LLC reissued a buy rating and set a $60.00 price target on shares of Amedisys in a research report on Thursday, October 12th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $60.00 price objective on shares of Amedisys in a research report on Monday, October 9th. BidaskClub cut shares of Amedisys from a strong-buy rating to a buy rating in a research report on Wednesday, July 12th. Finally, Mizuho reaffirmed a buy rating and issued a $65.00 price objective (up from $55.00) on shares of Amedisys in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $61.00.
Shares of Amedisys (AMED) traded down $0.14 during midday trading on Thursday, hitting $56.25. 310,900 shares of the stock were exchanged, compared to its average volume of 485,523. The company has a market capitalization of $1,908.96, a PE ratio of 26.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.68. Amedisys has a 52 week low of $38.00 and a 52 week high of $65.91. The company has a current ratio of 1.33, a quick ratio of 1.21 and a debt-to-equity ratio of 0.16.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The company had revenue of $380.20 million for the quarter, compared to analysts’ expectations of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the firm posted $0.36 earnings per share. analysts forecast that Amedisys will post 2.22 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Amedisys Inc (AMED) Earns “Buy” Rating from Craig Hallum” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/12/amedisys-inc-amed-earns-buy-rating-from-craig-hallum.html.
Hedge funds have recently modified their holdings of the business. Riverhead Capital Management LLC increased its stake in Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after buying an additional 831 shares during the last quarter. Federated Investors Inc. PA increased its stake in Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Amedisys in the 3rd quarter valued at $205,000. CIBC Asset Management Inc acquired a new stake in Amedisys in the 2nd quarter valued at $230,000. Finally, SG Americas Securities LLC increased its stake in Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock valued at $235,000 after buying an additional 1,226 shares during the last quarter. Hedge funds and other institutional investors own 96.36% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.